Median

NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

Retrieved on: 
Thursday, April 25, 2024
Amyloid, Pure autonomic failure, Protein, GDF15, Cell, Safety, AFL, Median, Neuroinflammation, Fluid mechanics, Corticobasal degeneration, Cytokine, Plasma, MD, Dementia, Latency, GFAP, IND, Frontotemporal dementia, Patient, Multiple system atrophy, UK Biobank, CSF, ADAS-Cog, Biomarker, Clinical trial, PD, NK, LTBP2, Pharmaceutical industry

90% of patients enrolled in the proof-of-concept Phase 1 Alzheimer’s trial had improved or stable cognitive function at week 11 using the composite ADCOMS score.

Key Points: 
  • 90% of patients enrolled in the proof-of-concept Phase 1 Alzheimer’s trial had improved or stable cognitive function at week 11 using the composite ADCOMS score.
  • NKGen submitted an IND for SNK01 in Parkinson’s disease (“PD”) in Q1 2024 and anticipates to begin enrollment for its Phase 2 trial in advanced Alzheimer’s disease (“AD”) in Q2 2024.
  • Cognitive assessments and extensive CSF/plasma biomarker analyses were performed at baseline and at 1 and 12 weeks after the final dose.
  • A larger Phase 2 placebo-controlled AD trial with a higher dosing and longer duration will begin to enroll in Q2 2024.

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

Retrieved on: 
Monday, March 25, 2024
Plasma, Conference, Tau, Cell, Disease, CSF, Patient, Biomarker, Research, Median, Asian literature, ADAS-Cog, Tau protein, Safety, NK, Amyloid, Pharmaceutical industry

SANTA ANA, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (“NK”) cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the Tau2024 Global Conference in Washington, D.C.

Key Points: 
  • The additional Phase 1 SNK01 trial data suggest clinical activity regarding cognitive function in patients with advanced Alzheimer’s disease in addition to previously disclosed positive effects on amyloid protein and neuroinflammation biomarkers.
  • Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed at baseline and at 1 and 12 weeks after the final dose.
  • “The data presented today demonstrate additional beneficial effects of SNK01 for the treatment of Alzheimer’s disease,” commented Paul Y.
  • While the results were positive, the Phase 1 trial was a dose-escalation trial that only administered four total doses over 11 weeks.

Conifer Realty, LLC and CPP Announce Rehabilitation and Preservation of Andrews Terrace in Rochester, New York

Retrieved on: 
Tuesday, January 9, 2024
Senior, Community, Genesee River, AMI, Downtown Rochester, HAP, CPP, KeyBank, SHPO, Housing, HTC, Goldman Sachs, National Park Service, Partnership, Federal, History, Conifer, HUD, CDLI, County, LIHTC, HVAC, Project, Median, UIG, Common

This is the second joint community investment for Conifer and CPP in Rochester, following Keeler Park, which was purchased in October 2022.

Key Points: 
  • This is the second joint community investment for Conifer and CPP in Rochester, following Keeler Park, which was purchased in October 2022.
  • In response to this, Andrews Terrace will receive extensive renovations estimated at $101 million, with a total project investment of approximately $335 million.
  • "We are excited to partner with Conifer Realty and Community Preservation Partners to revitalize Andrews Terrace, which provides a critical supply of affordable housing to Downtown Rochester.
  • Together with CPP, we look forward to preserving the legacy of Andrews Terrace and creating an even brighter future for its residents."

Hyundai Beats Everyone as Value Impacts Perceived Quality, According to Strategic Vision's 2023 Total Quality Awards

Retrieved on: 
Tuesday, October 31, 2023
Odyssey, BMW X6, MINI, Honda Accord, Chevrolet Blazer, Incidence, HMC, Hyundai Motor Company, Hyundai Elantra, Total quality management, GMC, Plan, Blazer, Median, Honda Odyssey, General Motors, GMC Sierra, Senior, American Honda Motor Company, Trust, Honda, Kia EV6, SAN, BMW, Hyundai, Chevrolet, Perception, GM, Excitation, Retail, Automotive industry, Value, Japanese domestic market, Individual

However, Hyundai Motor Corporation brands, as well as others, were able to provide vehicles with the fewest problems, generate love all magnified by perceptions of Value.

Key Points: 
  • However, Hyundai Motor Corporation brands, as well as others, were able to provide vehicles with the fewest problems, generate love all magnified by perceptions of Value.
  • HMC had the most vehicles lead their segments in Strategic Vision's 2023 Total Quality Awards, with six models, including the Hyundai Elantra, Elantra Hybrid, Santa Cruz, Palisade, Genesis G90, and Kia EV6, according to Strategic Vision's 2023 Total Quality Impactä (TQI) measure.
  • Strategic Vision's 2023 Total Quality Awards reflect the impact of vehicle Value on perceived quality.
  • Below is the full list of the 2023 Total Quality Award winners and TQI scores:

Median Technologies Reports 2023 Half-year Results and Business Indicators for the Third Quarter of 2023

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Technology, Health, Radiology, Oncology, Medical Devices, Research, Artificial Intelligence, Surgery, Science, Clinical Trials, Survival, FDA, LP, NMPA, Medical device, Q2, Lung cancer, Medicine, Mortality, US Foods, Chinese, Software, Euronext Growth, Q3, Business, Cave rescue, Survival rate, Patient, EIB, Diagnosis, LCS, Rare-earth element, Cryptocurrency, Pharmaceutical industry, Median

Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).

Key Points: 
  • Median Technologies (Euronext Growth – ALMDT:PA) (Paris:ALMDT), whose board of Directors approved the consolidated IFRS financial statements for the first half of 2023 on October 18, 2023, today announces its half-year results as well as business indicators for Q3 2023 (unaudited).
  • Commenting on the results, Fredrik Brag, CEO, and co-founder of Median Technologies, said:
    “During the first three quarters of 2023, we made significant strides regarding iBiopsy®.
  • These are key milestones in our roadmap to obtain marketing authorizations for our Software as Medical Device for the US and European markets.
  • Median is poised to play a pivotal role to help significantly reduce the lung cancer mortality rate through more effective diagnosis of early-stage patients.

Median Technologies Appoints Ben McDonald to its Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Technology, Health Technology, Radiology, Artificial Intelligence, Biotechnology, Citadel, Investment, Multimedia, Hospital, MBA, Physician, Biomarker, University, Artificial intelligence, Patient, Entrepreneurship, HBA, Software, Sale, Johnson Health Tech, Cryptocurrency, Management, Western University, Median

Median Technologies (Paris:ALMDT) announced today that Ben McDonald has joined its Board of Directors, chaired by Oran Muduroglu.

Key Points: 
  • Median Technologies (Paris:ALMDT) announced today that Ben McDonald has joined its Board of Directors, chaired by Oran Muduroglu.
  • Ben serves on the board of directors for Aegis Group Partners Holdco, Noble Biomaterials, SuperTurbo Technologies, and Next Generation Turbo.
  • «I’m thrilled to welcome Ben McDonald to the board of directors of Median Technologies.
  • “I am delighted to join the board of directors at Median Technologies.

Bright MLS July Housing Report: Mid-Atlantic Housing Market Resilient

Retrieved on: 
Friday, August 11, 2023
NORTH, MLS, Housing, Greater Richmond Region, Washington Metro, Appraiser, Marriage, Sale, Home, USDA, Divorce, FHA, Ebbs, Weather, Inventory, Cassette tape, Real estate, Bottled water, Grocery store, Palladium, Publishing, Del-Mar-Va Express, South Central Pennsylvania, Salient (geography), Mid-Atlantic (United States), Bright, Median, D.C

NORTH BETHESDA, Md., Aug. 11, 2023 /PRNewswire/ -- The Mid-Atlantic housing market stayed firmly on the summer pace set in June, as buyers still compete for historically-low levels of inventory even in the midst of an elevated mortgage rate environment, according to the Bright MLS Mid-Atlantic July Housing Report released today. The median home price in the region was up 3.9% in July, the strongest price growth since January.  

Key Points: 
  • "It's been surprising to me that higher rates and prices have not pushed more people out of the market, particularly first-time buyers," said Dr. Lisa Sturtevant, Bright MLS Chief Economist.
  • "It's been surprising to me that higher rates and prices have not pushed more people out of the market, particularly first-time buyers," said Dr. Lisa Sturtevant, Bright MLS Chief Economist.
  • No relief was found in the market for buyers, however, as new listings were down over 29% in the region.
  • Looking ahead, Bright expects the fall market in the Mid-Atlantic will be characterized by low inventory, stable or rising home prices, and growing affordability challenges.

Median Technologies Reports Full-year 2022 Results and Business Indicators for the First Quarter Of 2023

Retrieved on: 
Thursday, April 20, 2023
Oncology, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, Medical device, Malignancy, Euronext Growth, BofA Securities, Cave rescue, LCS, ECR, Lab, Bank statement, COVID-19, Lung cancer screening, Cancer, Lung cancer, Biomarker, European Congress of Radiology, Liver cancer, ASCO, Bent Image Lab, 2023 International Conference on Climate Resilient Pakistan, American Society of Clinical Oncology, Patient, Artificial intelligence, Diagnosis, AI, EIB, FDA, European Investment Bank, Society, Conference, Cryptocurrency, Pharmaceutical industry, Medical imaging, Median

Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial year ending December 31, 2022, today announces its full-year results for 2022 and business indicators (unaudited) for the first quarter of 2023.

Key Points: 
  • Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial year ending December 31, 2022, today announces its full-year results for 2022 and business indicators (unaudited) for the first quarter of 2023.
  • In the first quarter of 2023, we achieved revenue of €5.6 million, with an order backlog of €62 million at March 31.
  • In March 2023 , Median Technologies presented new results for the performance of its iBiopsy® LCS CADe/CADx SaMD.
  • On January 19, 2023 , Median reported business indicators for 2022 and now confirms the following audited figures:
    An order backlog at December 31, 2022 of €60.8 million;
    Cash and cash equivalents of €21.5 million at December 31, 2022.

Dwight Capital & Dwight Mortgage Trust Finance Over $136.5MM in November 2022

Retrieved on: 
Monday, December 12, 2022
Commercial Building & Real Estate, Construction & Property, Finance, Banking, Professional Services, Urban Planning, REIT, Residential Building & Real Estate, Fund, Capital, Kathryn Ann Clarke, FHA, Mezzanine, HUD, DMT, Median, Mortgage insurance, Paxton, Investment, REIT, OR, Real estate, Green

Dwight Capital and its affiliate REIT, Dwight Mortgage Trust , closed over $136.5MM of loans during November.

Key Points: 
  • Dwight Capital and its affiliate REIT, Dwight Mortgage Trust , closed over $136.5MM of loans during November.
  • Both refinances benefitted from a Green Mortgage Insurance Premium (MIP) Reduction set at 25 basis points because the properties achieved ENERGY STAR green certifications.
  • Dwight Capital LLC is one of the largest commercial real estate finance companies in the United States and has a loan servicing portfolio in excess of $11 billion.
  • For more information about Dwight Mortgage Trust, please visit: www.dwightmortgagetrust.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005547/en/

Median Technologies Communicates Its Business Indicators for the Second Quarter of 2022

Retrieved on: 
Monday, July 11, 2022
Software, Biometrics, Biotechnology, Health, Medical Devices, Data Management, Health Technology, Technology, Collection, Solution, FDA, COVID-19, CEO, BPI, Disease, LCS, AI, Medical device, Intellectual property, Marketing, Lung cancer, Bent Image Lab, SME, Element, Artificial intelligence, Forward-looking statement, Software, Cade, Cave rescue, ASCO, Mission statement, Cancer, Review, Federal Food, Drug, and Cosmetic Act, Data mining, Group, Research, Patient, Lists of diseases, Growth, Technology, Diagnosis, Renewable energy, Fine chemical, Medical imaging, Median

Median Technologies (ALMDT:PA) (Paris:ALMDT) today announces its business indicators for the first half of 2022.

Key Points: 
  • Median Technologies (ALMDT:PA) (Paris:ALMDT) today announces its business indicators for the first half of 2022.
  • Following record revenues in Q1 2022 of 5.7 million, Median Technologies continued its strong growth with Q2 2022 revenues of 7.0 million, which is a 43% increase versus Q2 2021 (4.9 million).
  • The growth momentum of our business continued during the second quarter of 2022, with record quarterly revenues, up 43% versus the same period year ago.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.